

University of Arkansas, Fayetteville ScholarWorks@UARK

Patents Granted

4-25-2001

Vaccine conjugate

Craig E. Whitfill

Tommy L. Fredericksen

Julius K. Tyczkowski

James P. Thaxton Jr.

John A. Thoma

University of Arkansas, Fayetteville

Follow this and additional works at: <http://scholarworks.uark.edu/pat>

Recommended Citation

Whitfill, Craig E.; Fredericksen, Tommy L.; Tyczkowski, Julius K.; Thaxton, James P. Jr.; and Thoma, John A., "Vaccine conjugate" (2001). *Patents Granted*. Paper 173.

<http://scholarworks.uark.edu/pat/173>

This Patent is brought to you for free and open access by ScholarWorks@UARK. It has been accepted for inclusion in Patents Granted by an authorized administrator of ScholarWorks@UARK. For more information, please contact scholar@uark.edu.



(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
25.04.2001 Bulletin 2001/17

(51) Int Cl.7: **A61K 39/42, A61K 39/12,**
A61K 39/00, A61K 35/14,
B65D 35/14

(21) Application number: **96111909.6**

(22) Date of filing: **01.10.1990**

(54) **Vaccine conjugate**

Impfstoffkonjugat

Conjugué vaccinal

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB IT LI LU NL SE

(30) Priority: **02.10.1989 US 416035**
15.02.1990 US 480678
24.09.1990 US 586859

(43) Date of publication of application:
29.01.1997 Bulletin 1997/05

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
90917281.9 / 0 495 008

(73) Proprietor: **UNIVERSITY OF ARKANSAS**
Fayetteville, Arkansas 72701 (US)

(72) Inventors:
• **Whitfill, Craig E.**
Apex, North Carolina 27502 (US)
• **Fredericksen, Tommy L.**
Ashford Connecticut 06178 (US)
• **Tyczkowski, Julius K.**
Cary, North Carolina 27511 (US)
• **Thaxton, James Paul, Jr.**
Brandon, Mississippi 39216 (US)
• **Thoma, John A., Dr.**
Fayetteville, Arkansas (US)

(74) Representative:
Bankes, Stephen Charles Digby et al
BARON & WARREN
18 South End
Kensington
London W8 5BU (GB)

(56) References cited:
DE-B- 1 041 214 **US-A- 4 493 825**
US-A- 4 530 831 **US-A- 4 645 665**
US-A- 4 824 668 **US-A- 4 867 975**
US-A- 4 956 452

- **PROC.SOC.EXP.BIOL.MED., vol. 128, 1968,**
pages 525-530, XP000611419 STONE ET AL:
"VACCINATION OF CONGENITALLY-IMMUNE
CHICKS AGAINST NEWCASTLE DISEASE
VIRUS (33057)"
- **AVIAN DISEASES, vol. 14, 1970, pages 579-586,**
XP000611206 HIGGINS: "INTERACTION OF
LENTOGENIC NEWCASTLE DISEASE VIRUS
AND SPECIFIC ANTIBODIES WITHIN THE YOLK
SAC"
- **ARCHIVES OF VIROLOGY, vol. 91, 1986, pages**
207-220, XP000609198 WETZ ET AL:
"NEUTRALIZATION OF POLIOVIRUS BY
POLYCLONAL ANTIBODIES REQUIRES
BINDING OF A SINGLE IGG MOLECULE PER
VIRION"

Remarks:

The file contains technical information submitted
after the application was filed and not included in this
specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] The present invention relates to a vaccine conjugate, comprised of a live virus and a neutralizing antibody or fragment thereof, and its use in producing active immunity in mammalian animal subjects.

5 **[0002]** Gyles et al., 47 *Poultry Sci.* 430 (1968), and Gyles and Brown, 50 *Poultry Sci.* 901 (1971), found that regression of Rous sarcoma virus (RSV)-induced tumors is under genetic control in Arkansas progressor line and Arkansas regressor line chickens. Whitfill et al., 61 *Poultry Sci.* 1573 (1982), reported a low molecular weight fraction that was isolated by gel permeation chromatography from Arkansas regressor chicken sera. The active low molecular weight fraction was called the low molecular weight viral neutralizing factor (VNF). See Whitfill et al., 17 *Immunogenetics* 387
10 (1983).

[0003] Gyles and Whitfill, *Annual Report of Project Contributions to NE-60* (Oct. 1986), subsequently reported that VNF neutralized Rous sarcoma virus and Newcastle's Disease virus when administered in combination therewith to nine day old SPAFAS egg embryos as measured by chorioallantoic membrane pock formation. Later, Gyles and Whitfill, *Annual Report of Project Contributions to NE-60* (Oct. 1987), reported that VNF neutralized Infectious Bursal Disease Virus (IBDV) and Infectious Bronchitis Virus (IBV) when administered in combination therewith to nine day old SPAFAS egg embryos, and had antimicrobial activity. It has not heretofore been suggested that VNF is a viral neutralizing antibody.

[0004] Viral neutralizing antibodies are antibodies which can neutralize the infectivity of a virus if the virus and antibodies are allowed to react together for a sufficient time. Such a procedure is carried out during the course of performing a neutralization test. The neutralization test, which was the first technique used to detect antibodies against virus in serum, can be done with virtually any virus. See generally *Handbook of Experimental Immunology*, 37.9 (D.M. Weir Ed. 2d ed. 1973)(Blackwell Scientific Publications).

20 **[0005]** N. Phillips, 33 *Vira. Agr. (Lima E. sum.)* 111 (1956)(Summarized in J. Vasington et al., 39 *Poultry Sci.* 1418, 1419 (1960)), in an attempt to confer immediate and lasting immunity against Newcastle Disease Virus in birds, studied the effect of plasma and yolk in combination with live virus. The plasma was obtained from birds that survived a natural outbreak of the disease and the yolk was obtained from eggs produced by the same birds. The results of these studies showed that all chickens receiving simultaneous inoculations of the plasma-yolk mixture and virus, and those which received the virus two days later, survived challenge with artificial inoculation.

[0006] J. Vasington et al., 39 *Poultry Sci.* 1418 (1960), investigated the protective value of Newcastle Disease Virus immune serum and gamma globulin against Newcastle Disease virus challenge in 4 to 5 week old chickens. Challenge was carried out simultaneous with or subsequent to administration of the immune serum or gamma globulin. Simultaneous administration of NDV and gamma globulin in one bird was found to protect the bird against death, but did not lead to active immunity. See *Id.* at 1424 Table 4 and accompanying text. It is not suggested that the virus and antibody be administered as a complex.

35 **[0007]** H. Stone and W. Boney, 128 *P.S.E.B. Med.* 525 (1968), report the vaccination of 1-2 day old chicks against Newcastle Disease Virus with a vaccine containing chemically inactivated virus antigen in the form of antigen-antibody complexes, free homologous antibody, and an aluminum hydroxide adjuvant. The complexing of the antigen with the inactivated virus did not lead to increased protection against challenge, see *Id.* at 528, and the data indicated that the use of an adjuvant was critical to the results.

40 **[0008]** D. Higgins, 14 *Avian Diseases* 579, 585 (1970), notes that the presence of maternal neutralizing antibodies in the yolk of eggs from hens immune to Newcastle's Disease Virus (NDV) is well known. Higgins suggests that, if the antibody-antigen complex formed after yolk sac inoculation of NDV diffuses throughout the embryonic tissues prior to hatching, as do uncombined yolk sac antibodies, and persists in the neonatal chick, it may later stimulate active anti-NDV immunity. Higgins does not suggest that neutralizing antibodies be complexed with a live virus to attenuate that virus, and the complex then administered as a vaccine.

45 **[0009]** Platt et al., US-A 4,493,825, disclose a vaccine complex comprised of an immunizing agent with an antibody bound thereto, the antibody in turn having a microparticle bound thereto. Pathogenic microorganisms, whole virus, and antigenic proteins are suggested as immunizing agents. The authors state that the ability to use such complexes as vaccines is surprising, because the immunizing activity of the antigenic protein would have been thought to have been interfered with by the antibody binding. See Col. 2, lines 14-17 therein. The authors do not suggest that their vaccine would be operable without the inclusion of the microparticle, do not suggest that neutralizing antibodies be used, do not suggest that live virus capable of causing disease (i.e., pathogenic) be used, do not suggest that the conjugation of an antibody to a live virus will protect a subject against infection by that live virus, and do not suggest that a neutralizing antibody should be used to obtain protection against infection by a pathogenic live virus when a pathogenic live virus
50 is used as the immunizing agent.

[0010] K. Fahey et al., 70 *J. Gen. Virol.* (1989), disclose a viral neutralizing antibody to IBDV. The antibody, which was monoclonal in origin, was used to separate a structural protein from solubilized viral particles for the purpose of developing a subunit vaccine for IBDV. It is not suggested that the viral neutralizing antibody would protect a subject

against IBDV so that the IBDV, with the neutralizing antibody bound thereto, could be administered as a live vaccine.

[0011] The present invention is based on our ongoing efforts to characterize Viral Neutralizing Factor (VNF). During this research, the active component of prior preparations of VNF was unexpectedly found to be a higher molecular weight contaminant in these generally lower molecular weight preparations. Specifically, VNF was found to be a viral neutralizing antibody. This finding makes available new uses of viral neutralizing antibodies, and fragments thereof, in the production of live attenuated viral vaccines. In view of the tendency of maternal antibodies in chicks to interfere with the development of active immunity to a live virus challenge, see P. Abdu et al., *Worlds Poultry Science V 42*, 219, (1968); P. Sharma et al., *Zootecnica Internacional*, 51 (June 1989), these results are particularly unexpected.

[0012] The preparation of the present invention can accordingly be used to produce active immunity against a viral disease in an animal subject. The vaccine conjugate is administered in an amount effective to produce an immune response to the live virus in the animal subject. The vaccine conjugate comprises:

a live vaccine virus capable of causing said viral disease in the mammalian animal subject and capable of producing an active immune response thereto in said animal, and

bound to said vaccine virus a neutralising factor in the form of an antibody or antibody fragment capable of neutralising said virus, said vaccine conjugate initially protecting the animal from infection by said vaccine virus,

the vaccine conjugate being present in an amount sufficient to allow said vaccine virus to stimulate active immunity against further challenge with said virus.

[0013] Another aspect of the present invention is a vaccine preparation useful for producing active immunity against a viral disease in an animal subject. The vaccine preparation is a pharmaceutically acceptable formulation which comprises a vaccine conjugate. The vaccine conjugate comprises a live virus and a neutralizing factor bound to the live virus. The neutralizing factor is selected from the group consisting of antibodies and antibody fragments. The antibody or antibody fragment is capable of neutralizing the live virus. The vaccine conjugate is included in the pharmaceutically acceptable formulation in an amount effective to produce an immune response to the live virus in the subject.

[0014] EP-B-0495008, from which the present application is divided, describes and claims the use of a vaccine conjugate of the type described above for the manufacture of a medicament for producing active immunity against a viral disease in a bird, the conjugate initially protecting the bird from infection by the vaccine virus and subsequently allowing the vaccine virus to stimulate active immunity against further challenge with the virus.

[0015] Another aspect of the present invention is an article of manufacture comprising a closed, pathogen-impermeable, container and a sterile vaccine formulation as described above enclosed within the container.

[0016] Preferred embodiments of the invention will now be described with reference to the accompanying drawings wherein:

[0017] Figures 1, 2, and 3 schematically illustrate the various preparations from Arkansas regressor line chicken sera that have been used for the purification of VNF and the determination of relative VNF activities.

[0018] Figure 4 illustrates the elution profile of the $\geq 50k$ sera component of Arkansas regressor line chicken sera by TSK chromatography.

[0019] Figure 5 illustrates, by TSK chromatography, the elution profile of the peak I component shown in Figure 4.

[0020] Figure 6 illustrates the elution profile, by TSK chromatography, of the peak II component shown in Figure 4.

[0021] Figure 7 illustrates the elution profile, by TSK chromatography, of the peak III component shown in Figure 4.

[0022] Figure 8 illustrates the elution profile of the $\geq 100k$ sera component of Arkansas regressor line chicken sera by TSK chromatography.

[0023] Figures 9 through 11 illustrate the increased purification of VNF achieved by first, second, and third recyclings of the peak II component illustrated in Figure 8 through a TSK chromatography column.

[0024] Figure 12 illustrates, by TSK chromatography, the purity of VNF prepared by prior techniques.

[0025] The following description relates mainly to the treatment of birds, as claimed in the parent patent EP-B-0495008, but it will be understood that the principles illustrated are also applicable to mammals.

[0026] Antibodies used in practicing the present invention are viral neutralizing antibodies. Viral neutralizing antibodies are those which combat the infectivity of a virus *in vitro* if the virus and the antibodies are allowed to react together for a sufficient time. The source of the viral neutralizing antibody is not critical. They may originate from any animal, including birds (e.g., chicken, turkey) and mammals (e.g., rat, rabbit, goat, horse). The viral neutralizing antibodies may be polyclonal or monoclonal in origin. See, e.g., D. Yelton and M. Scharff, 68 *American Scientist* 510 (1980). The antibodies may be chimeric. See, e.g., M. Walker et al., 26 *Molecular Immunology* 403 (1989). The antibodies may be of the type heretofore known as Viral Neutralizing Factor (VNF). See, e.g., Gyles and Whitfill, *supra*. VNF used for practicing the present invention may be obtained from the Giant Jungle Fowl (*Gallus gallus*) and strains of birds derived from *Gallus gallus* which are capable of producing VNF. Exemplary of such derivative strains is the Arkansas regressor chicken line. Among other means, stocks of birds can be located through the International Registry of Poultry Genetics Stocks, Bulletin No. 476, Agriculture Publication No. U-351376 (available from the University of Connecticut, Storrs,

Connecticut).

[0027] Viral neutralizing antibodies used in practicing the present invention may be immunoglobulins of any isotype, including IgM, IgG, IgA, IgD, and IgE immunoglobulins. IgG and IgM are more preferred, and IgG immunoglobulins (e. g., IgG1, IgG2, IgG3, IgG4) are most preferred.

[0028] Antibody fragments used in practicing the present invention are fragments of viral neutralizing antibodies which retain the variable region binding site thereof. Exemplary are F(ab')₂ fragments, F(ab') fragments, and Fab fragments. See generally Immunology: Basic Processes, 95-97 (J. Bellanti Ed. 2d ed. 1985).

[0029] Antibodies or antibody fragments used in practicing the present invention may have additional elements joined thereto. For example, a microsphere or microparticle may be joined to the antibody or antibody fragment, as described in U.S. Patent No. US-A 4,493,825.

[0030] The present invention uses viruses which would be pathogenic (i.e., capable of causing disease) in the subject being treated if not for their conjugation to the neutralizing factor. The pathogenicity of the virus may be inherent in the virus itself or due to the susceptibility of the subject to be treated. In general, many pathogenic viruses have the positive effect of evoking active immunity in subjects infected therewith, and many attenuated vaccine strains of virus have the capability of causing at least some disease in subjects. Hence, the term "pathogenic," as used to describe viruses herein, means that the harm caused to subjects by administration of the virus outweighs any benefit which would result therefrom. It is preferred that the virus be one capable of producing an active immune response thereto in the subject being treated.

[0031] The vaccine conjugate is included in the vaccine formulations in an amount per unit dose sufficient to evoke an active immune response to the virus in the subject to be treated. The term "immune response," as used herein, means any level of protection from subsequent exposure to the virus which is of some benefit in a population of subjects, whether in the form of decreased mortality, decreased lesion scores, improved feed conversion ratios, or the reduction of any other detrimental effect of the disease, regardless of whether the protection is partial or complete.

[0032] With respect to the degree of protection provided by the neutralizing factor, the quantity of the neutralizing factor administered in combination with the virus in the vaccine need not be sufficient to provide complete protection from the virus, as long as the detrimental response produced by the virus is reduced to a level at which the benefits of the immune response produced outweigh any harm resulting from the infection.

[0033] Exemplary of mammalian viruses which may be mixed with the neutralizing factor to form a vaccine are the Japanese Encephalitis Virus, Influenza Virus, Sendai Virus, Measles Virus, Human Influenza Virus and Pseudorabies. See e.g., U.S. Patents Nos. 4,659,569 and 4,493,825.

[0034] The term "Infectious Bursal Disease Virus" (IBDV), as used herein, encompasses all strains of IBDV. Exemplary are the Bursal Disease Vaccine, Lukert strain, live virus, which is obtained from either Vineland Laboratories in Vineland, New Jersey or Salsbury Laboratories in Charles City, Iowa, the Bursal disease virulent challenge virus, which is obtained from the U.S.D.A. in Ames, Iowa (original isolate from S. A. Edgar), and Infectious Bursal Disease Virus strain VR2161, disclosed in U.S. Patent No. 4,824,668 to Melchior and Melson.

[0035] The term "Rous Sarcoma Virus" (RSV), as used herein, encompasses all strains of RSV. RSV, has been comprehensively studied since its discovery early this century. See generally 1 RNA Tumor Viruses: Molecular Biology of Tumor Viruses, Second Edition, 59-61 (R. Weiss, N. Teich, H. Varmus and J. Coffin eds. 1984). An assay technique for Rous Sarcoma Virus is reported at Brit. J. Exptl. Med., 99:183. Moloney, J. Nat. Cancer Inst., 16:877, reports the development of standard lots of the virus for use in quantitative investigations. See also U.S. Patent No. 3,326,767 to Holper and Kiggins. Numerous Rous sarcoma virus strains are listed in the ATCC Catalogue of Animal and Plant Viruses, Chlamydiae, Rickettsiae and Virus Antisera (5th ed. 1986), at pages 110-112.

[0036] The term "Infectious Bronchitis Virus" (IBV), as used herein, encompasses all strains of IBV. Exemplary are Mass. 41 Strain, Arkansas 99 Strain, Connecticut A5968, and Michigan State University Repository Code 42 Strain, all available from American Type Culture Collection, Rockville, Maryland. The term "Newcastle's Disease Virus" encompasses all strains of Newcastle's Disease Virus.

Exemplary mammals include mice, rats, guinea pigs, rabbits, ferrets, dogs, cats, cows, horses and primates including man.

[0037] Animals may be administered vaccines of the present invention by any suitable means. Exemplary are by oral administration, by intramuscular injection, by subcutaneous injection, by intravenous injection, by intraperitoneal injection, by eye drop or by nasal spray.

[0038] A vaccine conjugate of the present invention is made by mixing the neutralizing factor with a live virus in a pharmaceutically acceptable carrier for a time sufficient to form a live virus-neutralizing factor conjugate (for example, by combining the neutralizing factor and virus in a common liquid carrier for at least about one hour prior to administration to a subject). This can advantageously be carried out by simply adding hyperimmune sera containing VNF to an aqueous solution containing the live virus. Vaccine formulations of the present invention preferably comprise the vaccine conjugate in lyophilized form or the vaccine conjugate in a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are preferably liquid, particularly aqueous, carriers. For the purpose of preparing such vaccine

formulations, the neutralizing factor and virus may be mixed in sodium phosphate-buffered saline (pH 7.4) or conventional media such as MEM. The vaccine formulation may be stored in a sterile glass container sealed with a rubber stopper through which liquids may be injected and formulation withdrawn by syringe.

5 [0039] Vaccine formulations of the present invention may optionally contain one or more adjuvants. Any suitable adjuvant can be used, including chemical and polypeptide immunostimulants which enhance the immune system's response to antigens. Preferably, adjuvants such as aluminum hydroxide, aluminum phosphate, plant and animal oils, and the like are administered with the vaccine conjugate in an amount sufficient to enhance the immune response of the subject to the vaccine conjugate. The amount of adjuvant added to the vaccine conjugate will vary depending on the nature of the adjuvant, generally ranging from 0.1 to 100 times the weight of the virus, preferably from 1 to 10 times the weight of the virus.

10 [0040] The vaccine formulations of the present invention may optionally contain one or more stabilizers. Any suitable stabilizer can be used, including carbohydrates such as sorbitol, manitol, starch, sucrose, dextrin, or glucose; proteins such as albumin or casein; and buffers such as alkaline metal phosphate and the like. The use of a stabilizer is particularly advantageous when the vaccine formulation is a lyophilized formulation.

15 [0041] The present invention is described in greater detail in the following Examples. These examples are provided for illustrative purposes only,

EXAMPLE 1

20 Experimental Animals

[0042] The birds used for challenge with Rous sarcoma virus and subsequent sera collection were of the Arkansas regressor chicken line and the Arkansas regressor chicken line described in Gyles *et al.*, 46 Poultry Sci. 465 (1967), flocks of which are maintained at the Agricultural Research Farm of the University of Arkansas, Fayetteville, Arkansas, 25 72701.

EXAMPLE 2

30 Standard Inoculum of Rous Sarcoma Virus

[0043] A standard inoculum of RSV-RAV-1 to be used to stimulate the production of antiviral factor in regressor chicken sera was prepared with an RSV-RAV-1 Bryan High Titer Strain identified as Lot #1 prepared for American Type Culture Collection in Rockville, Maryland by Dr. John P. Bader, NCI, NIH. The titer was 2×10^6 PFU per milliliter and was stored at -70°C before use. Inoculation of birds was accomplished by infecting a standard inoculum of 0.1 milliliter of diluted RSV-RAV-1 into the left wing web as described in Whitfill *et al.*, 61 Poultry Sci. 1573 (1981). 35

COMPARATIVE EXAMPLE A

40 Preparation of Regressor Chicken Hyperimmune Sera

[0044] The object of this example is to demonstrate for comparative purposes prior procedures for preparing tumor homogenate from susceptible chickens to be used to boost regressor chickens to induce production of viral neutralizing factor from hyperimmune sera. Regressor chickens were challenged with a standard inoculum of RSV, and after complete tumor regression as measured by visible disappearance of tumors, were injected once weekly for at least three weeks with a standard inoculum of Rous sarcoma tumor homogenate (RSTH) booster. Five days after the last booster RSTH injection, 20 milliliters of blood was removed from each chicken by cardiac puncture and allowed to clot for one hour at room temperature. Clotted blood was sedimented at $3000 \times g$ at room temperature in a Sorvall centrifuge for ten minutes and hyperimmune sera was removed and stored at 5 degrees Celsius. This routine was continued for several weeks on a given group of donor regressor chickens. 50

COMPARATIVE EXAMPLE B

55 Preliminary Purification of Low Molecular Weight Antiviral Factor (LMF)

[0045] The object of this example is to demonstrate for comparative purposes prior techniques for partially purifying viral neutralizing factor from a large volume of hyperimmune regressor chicken sera. Approximately 400 milliliters of regressor chicken hyperimmune sera prepared according to Comparative Example A above was applied to a Sephadex® G-25 fine column (8 x 35 centimeters) and eluted at 250 milliliters per hour with 0.005M sodium phosphate buffer,

EP 0 755 684 B1

pH 7.0. Four peaks were eluted from the column and peak IV, the last to elute at 2800 milliliters, contained the VNF activity against RSV-RAV-1. Peak IV was shown to neutralize RSV-RAV-1 by incubation with the virus with subsequent injection into wing-webs of susceptible chickens, as previously described for Sephadex® G-100 fraction II. See Whitfill et al., 61 Poultry Sci. 1573 (1981). Peak IV typically eluted in a total volume of 1000 milliliters of buffer at 28 milliliters per tube and was freeze dried and redissolved at a concentration of 100 milligrams per milliliter in sterile distilled water.

COMPARATIVE EXAMPLE C

Further Purification of Sephadex® G-25 Peak IV Utilizing Biogel® P-2 Column Chromatography

[0046] The object of this Example is to demonstrate for comparative purposes prior techniques for the further purification and desalting of viral neutralizing factor from earlier preliminary active fractions utilizing gel filtration column chromatography.

[0047] Approximately 35 milliliters of redissolved Sephadex® G-25 peak IV (3500 milligrams) obtained as described in Comparative Example B above was applied to a Biogel® P-2 column (5 centimeters x 40 centimeters), and eluted in distilled water at a flow rate of 90 milliliters per hour. The antiviral activity was found against RSV-RAV-1 in the first peak (Peak I) eluting at the void volume after 390 milliliters at 14 milliliters per tube. This peak I, eluting in a total volume of 100 milliliters, was freeze dried to dryness and the salt free preparation represented the more highly purified preparation of VNF. Approximately 5-10 milligrams of further purified VNF typically resulted from peak I of the biogel P-2 column. A stock solution of the VNF in phosphate-buffered saline or distilled water was freshly prepared to a concentration of 5 milligrams per milliliter before testing for activity.

[0048] One activity unit for this stock solution is defined as the amount of activity against Rous sarcoma virus in one milliliter of this VNF solution. One milliliter of this solution will completely neutralize 500 standard doses of Rous sarcoma virus. A standard dose of Rous sarcoma virus is defined as that dilution of virus in 100 microliters that will produce an average of 70 pocks on SPF nine day old embryo chorioallantoic membranes by day 16. VNF is not toxic to a preparation of 7×10^4 chicken fibroblasts until a dose level of 0.1 Activity Unit is reached.

EXAMPLE 3

Preparation of Delipidated Regressor Line Hyperimmune Sera

[0049] This example demonstrates the currently preferred technique for preparing regressor chicken Hyperimmune Sera. The sera was prepared as described in Comparative Example A above, except that clotted blood was centrifuged at 3000 rpm for 15 minutes to remove particulate matter, and the resulting sera then filtered through a 5 μ m, 1.2 μ m, and 0.45 μ m filter respectively. Finally, the sera is passaged through C18 cartridges to remove the lipid contained in the sera.

EXAMPLE 4

Concentration and Hollow Fiber Filtration of Delipidated Hyperimmune Sera

[0050] A schematic overview of the currently preferred procedure for purifying VNF is given in Figures 1, 2, and 3. This example gives additional information on the procedures described in these Figures.

[0051] A sera prepared as described in example 3 above is circulated through a Spectrum® 50k or 100k hollow fiber breaker (available from Spectrum, Los Angeles, California, USA) and concentrated at least 4 fold for the greater than 50,000 molecular weight fraction ($\geq 50k$ sera component) or the greater than 100,000 molecular weight fraction ($\geq 100k$ sera component). Either the $\geq 50k$ sera or the $\geq 100k$ sera component is further fractionated on a preparative TSK® column in accordance with the procedures described in Example 5 below, with the VNF being contained in the 150k to 180k portion of each sera component.

EXAMPLE 5

Separation of $>50k$ or $>100k$ Sera Components On a Preparative TSK® Column

[0052] A preparative Spherogel TSK® 2000 SW column measuring 21.5 mm by 60 cm is run in 3x phosphate buffered saline at a flow rate of 8 ml per minute to separate the $\geq 50k$ and $\geq 100k$ sera components into the fractions shown in Figure 4 or Figure 8. Peak percentages for Figures 4 and 8 are given in Tables 1 and 2 below. Note that the time for the elution for peaks will vary slightly depending on experimental parameters such as the use of precolumns and slight

EP 0 755 684 B1

variations in buffers. By recycling the greater than 50K fractions back through the column, the peaks I, II, or III are partially isolated one from the other. These are shown in Figure 5 (Peak I of Fig. 4 at 5.89 minutes), Figure 6 (peak II of Fig. 4 at 6.71 minutes), and Figure 7 (peak III of Fig. 4 at 7.86 minutes) respectively. The viral neutralizing activity is located only in Peak II as it was shown to contain the greatest amount of specific activity.

5

TABLE 1

Peak Percentages for Figure 4			
Peak	Retention Time	Area Percent	Height Percent
I	5.88	4.2%	14.3%
II	6.72	25.7%	27.9%
III	7.79	58.0%	46.3%

10

15

TABLE 2

Peak Percentages for Figure 8			
Peak	Retention Time	Area Percent	Height Percent
I	5.92	2.4%	10.9%
II	7.02	23.6%	34.0%
III	8.39	72.1%	53.1%

20

[0053] Figures 8, 9, 10, and 11 show how Peak II of Fig. 8 is further purified by continued recycling through the TSK® column. This mixture of unpurified ≥100k sera components was initially labelled 5069a, then with further purification, 5070a, 5077a, and finally 5079a, which is the most highly purified form. As shown by the Figures, each time the peak II section eluting from the TSK column is cut and recycled, it becomes further purified and the specific activity is increased. The peak percentages for Figure 11 are given in Table 3 below. Activity Units for the highly purified IgG fraction containing active VNF are calculated as follows. The ED₅₀ titer against IBDV is determined using viral neutralization assays as described below. The ED₅₀ titer is the dilution of VNF in 50 μl that will protect 50% of the cells from being killed by the virus. Calculations are based on arbitrarily assigning an ED₅₀ dilution titer of 1:25 as being equal to 1 Activity Unit. The actual ED₅₀ titer for the specific preparation of VNF is then converted to units per milliliter and finally units per microgram which is defined as the specific activity (see Tables 5-7 for examples of this calculation).

25

30

35

TABLE 3

Peak Percentages for Figure 11			
Peak	Retention Time	Area Percent	Height Percent
I	4.91	0.5%	1.0%
II (IgG)	7.01	98.7%	97.1%
IV	12.39	0.9%	1.8%

40

COMPARATIVE EXAMPLE D

45

Purity of P-2 Peak I From Comparative Example C by TSK Chromatography

[0054] This Example demonstrates the lack of purity in previous preparations of VNF. A stock solution of VNF prepared as described in Comparative Example C above was applied to a TSK chromatography column as described in Example 5 above. The elution profile is given in Figure 12, and the percentages for each peak is given in Table 4 below. Note that the area percent for IgG is only 18.4%. Compare this Table to Table 3.

50

TABLE 4

Peak Percentages for Figure 12			
Peak	Retention Time	Area Percent	Height Percent
I (Macroglobulins)	5.55	5.9%	18.9%

55

EP 0 755 684 B1

TABLE 4 (continued)

Peak Percentages for Figure 12			
Peak	Retention Time	Area Percent	Height Percent
II (IgG)	6.26	18.4%	28.2%
III (Albumin)	6.86	44.1%	31.0%
IV (Low Molecular Weight Contaminant)	10.51	14.3%	10.0%
V (Low Molecular Weight Contaminant)	11.41	15.8%	9.8%

EXAMPLE 6

SDS-PAGE of Purified VNF Fractions

[0055] SDS-polyacrylamide gel electrophoresis (SDS-PAGE) separations of the most highly purified VNF components obtained in the foregoing Examples conclusively identify VNF as an IgG immunoglobulin.

[0056] 10 cm by 10 cm gels for SDS-PAGE having a gradient that separates in the 5,000 to 200,000 MW range were obtained from ISS-Enprotech of Hyde Park, Massachusetts, USA. On such gels, Peak II behaves identical to chicken IgG in that it produces 65,000 and 25,000 MW components in the presence of 2-mercaptoethanol (2-ME). On such gels, but without 2-ME, Peak II migrates with a major band at about 180,000 MW, as does chicken IgG.

EXAMPLE 7

Chicken Fibroblast Assay

[0057] The chicken fibroblast assay is useful as an *in vitro* screen for identifying VNF activity. It is useful for confirming the purification of VNF from a known source or confirming the presence of VNF in a perspective source. Our assay is based on standard procedures developed by J. Skeeles et al., 23 Avian Dis. 95 (1979). See also Diseases of Poultry, 574 (M. Hofstad Ed., 8th ed. 1984). In brief, fibroblasts are harvested from 9-11 day old specific pathogen-free embryos, grown to a thin layer in culture dishes on Complete Minimal Essential Media, and transferred to microtiter plate wells containing Infectious Bursal Disease Virus (Lukert's Strain) (IBDV). When desired, the IBDV in the microtiter plate is mixed prior to addition of the fibroblast cells with a preparation containing VNF, or suspected of containing VNF, to determine the presence or absence, or degree of, viral neutralizing activity in the preparation. Incubation of IBDV with a prospective neutralizing preparation is carried out for about one hour at 37°C. We determine the end-point of our assay with a MTT Dye reduction assay. Specific aspects of our procedure are given below.

A. Preparation of Fibroblasts for Use in Microtiter Plates.

[0058]

1. Harvest and culture fibroblasts.
2. After cells have become confluent, remove the media from the tissue culture dishes (Falcon 150x25 mm) and trypsinize with 15-20 mLs of trypsin. Placing the plates in the incubator for 2-5 minutes after adding the trypsin will help the cells to release from the dish quicker than at room temperature.
3. After the cells have released from the dishes, add 5 mLs of Newborn Calf Serum to neutralize the trypsin. Gently swirl the dishes to thoroughly mix the serum with the trypsin.
4. Pipette the trypsin/serum and cells from the dishes into equal aliquots in 50 mL centrifuge tubes. It is helpful to tilt the plate slightly on the side and to rinse the plate with the trypsin/serum mixture to release any adhering cells. Bring the volume of the tubes up to the 40 mL mark with MEM with 5% FCS to neutralize any remaining trypsin.
5. Spin the mixture in the tubes for 10 minutes at 1500 rpm at 16°C.
6. After spinning, pour off the supernatant and add 10 mLs of MEM with 5% FCS to each tube. Mix the cells with a pipette to break up any clumps. Combine all aliquots into one container and mix well.
7. From the combined aliquot, remove a small portion and prepare a 1:10 or 1:20 dilution in MEM with 5% FCS (a 1 mL + 9 mL dilution is usually sufficient to get a representative sample, but a 1 mL + 19 mL dilution will reduce

EP 0 755 684 B1

the number of cells to count).

8. Count the diluted cells on a hemacytometer and dilute in MEM with 5% FCS to make a 0.5×10^6 cells/mL solution.

9. Add 200 μ L of the cell solution to the desired wells of a microtiter plate using a multichannel pipetter. The cell solution must be kept well mixed in order to keep an even dispersal of cells within all the wells. If 15-20 mLs of the cell solution are placed in a sterile petri dish and replenished with freshly mixed cells between each couple of plates, this will help to insure even dispersal of cells into all wells.

B. Incubation of Microtiter Plates.

[0059] Incubate microtiter plates for 2 days in a 37°C incubator with 5.5% CO₂. Plates may be observed under a microscope after 1-2 days for preliminary test results or to check for visible contamination. Contamination may appear as cloudiness or small black specks in the media.

C. MTT Tetrazolium Dye Reduction Assay for Proliferation or Neutralization.

[0060]

1. Mix a 5 mg/mL solution of MTT tetrazolium dye (obtained from U.S. Biochemical Corp., Cleveland, Ohio) in 1x PBS. Not all of the crystals will dissolve. Filter sterilize through a .45 μ m syringe filter under a sterile hood.

2. Under a sterile hood, remove 100 μ L of liquid from each well in each plate. "Pulse" the plates by adding 20 μ L of MTT to each well after the liquid is removed. Return plates to the incubator for 3 hours.

3. After incubation, remove 100 μ L of solution from each well of the plate and discard (this step does not have to be sterile).

4. Add 100 μ L of Acid Isopropanol (40 mL 1N HCl or 3.3 mL 12 N HCl in 1 liter isopropanol) to each well.

5. Mix on a shaker for 1 minute at medium high speed (position 6 on a Dynatech Shaker).

6. Read OD within 30 minutes using a wavelength of 570 nm.

7. Calibrate to 0 absorbance with medium + MTT.

8. Read with an appropriate software program (i.e., Immunosoft™) and template on a microplate reader.

EXAMPLE 8

Viral Neutralizing Activity of Various Serum Fractions Against Infectious Bursal Disease Virus in the Chicken Fibroblast Assay

[0061] The various serum fractions described in Examples 3 to 6 above were tested for activity against IBDV in accordance with the procedures described in Example 7 above. These data are given in Tables 5 and 6 below. Peak II was the only fraction containing the majority of viral neutralizing activity. In all cases, the specific activity was greatest for Peak II and greatest for the most highly purified form of peak II (5079b, peak II - Table 7, or 5079a - Table 8). The relative percentage of active VNF contained in the peak II IgG fraction varies from one serum preparation to another. Figure 3 and Figures 8-11 show the purification scheme and profiles of purifying the IgG fraction containing VNF. Tables 5-7 show the activities of various fractions from the TSK®2000 column. Fraction 5079a activity is shown in Table 8. This 5079a fraction was fractionated into 5079b, peak I, which contained very low levels of macroglobulin contaminants, and 5079b, peak II, which contained the IgG fraction. Table 7 shows that 5079b, peak II contains the VNF activity.

TABLE 5

Virus Neutralization Activity of High and Low Molecular Weight Serum Factors Against Infectious Bursal Disease Virus (IBDV) ^{1,2,3}						
Sample #	Origin	Titer ED50	Units/50 μ l	Units/ml ⁴	Protein (μ g/ml)	Specific Activity (Units/ μ g)
5046	\geq 50K (S) ⁵	11,220	448.8	8976	60,350	0.1

¹HyVAC chicken fibroblasts at 1×10^5 cells/well in 200 μ l volume were used in assay.

²Various fractions were tested in 5 fold dilutions through 1:15,625 in 50 μ l volumes/well.

³Virus used was Leukerts Strain IBDV at 1:100 dilution in 50 μ l volume well.

⁴Calculations based on 1:25 dilution = 1 unit of activity in 50 μ l volume.

⁵S = Spectrum Hollow Fiber, Sar = Sartorius membrane system.

EP 0 755 684 B1

TABLE 5 (continued)

Virus Neutralization Activity of High and Low Molecular Weight Serum Factors Against Infectious Bursal Disease Virus (IBDV) ^{1,2,3}						
Sample #	Origin	Titer ED50	Units/50µl	Units/ml ⁴	Protein (µg/ml)	Specific Activity (Units/µg)
5*21	Peak	22.4	0.89	20	123	0.2
5*221	I-TSK Peak	25.7	1.02	21	26	0.8
5*332	II-TSK Peak	4	0.16	3.2	110	0.0
5061	III-TSK ≥100K (S)	1,778	71	1422	19,120	0.1
5062	≤100K (S)	2	0.08	1.6	90	0.0
5032	≤20K (Sar) ⁵	46.7	1.86	37.3	660	0.1

¹HyVAC chicken fibroblasts at 1×10^5 cells/well in 200 µl volume were used in assay.

²Various fractions were tested in 5 fold dilutions through 1:15,625 in 50 µl volumes/well.

³Virus used was Leukerts Strain IBDV at 1:100 dilution in 50 µl volume well.

⁴Calculations based on 1:25 dilution = 1 unit of activity in 50 µl volume.

⁵S = Spectrum Hollow Fiber, Sar = Sartorius membrane system.

TABLE 6

Virus Neutralization Activity of Various Serum Fractions Against Infectious Bursal Disease Virus (IBDV) With Increased Purification of Active Factor						
Sample #	Origin	Titer ED50	Units/50µl	Units/ml	Protein (µg/ml)	Specific Activity (Units/µg)
5069	≥100K (I,II, III)	7,782	711.3	14,226	90,443	0.2
5070	Peaks I, II, III (1st TSK)	4,168	166.7	3,334	12,923	0.3
5077	Peak II (2nd TSK)	1,000	40	800	1,073	0.7
5075	HMW ≤20K Sartorius	123	4.9	98	255	0.4
P2	Comp. Ex. C	60.2	2.4	48	91	0.5

EP 0 755 684 B1

TABLE 7

Virus Neutralization Activity of Chicken Sera Factors at Various Stages of Purification Against Infectious Bursal Disease Virus						
Sample #	Origin	Titer ED50	Units/50 μ l	Units/ml	Protein (μ g/ml)	Specific Activity (Units/ μ g)
5079b (I)	Further purified 5079a into peak I	354	14	280	5,400	0.1
5979b (II)	Further purified 5079a into peak II (IgG)	316	12.6	252	350	0.7
5069a	(I, II, III) \geq 100K (S)	16,982	679	13,580	90,443	0.2
5070a	I, II, III (1st TSK Prep)	12,589	503	10,060	34,125	0.3
5077a	II-(2nd TSK Prep)	5,011	200	4,000	6,720	0.6

EXAMPLE 9

Viral Neutralizing Factor Found in Sera From Other Regressor Lines of Chickens with the Chicken Fibroblast Assay

[0062] These experiments were carried out in essentially the same manner as the experiments described in Example 8 above, except that alternate sources for Viral Neutralizing Factor were tested. The data for these experiments are given in Table 8 below. Table 8 also compares the regressor sera with HyLine sera. These data indicate that sera from the East Lansing regressor lines of chickens tested do not contain significant VNF activity. In addition, it was found that Sera from unchallenged Arkansas Regressor birds contains VNF, and that sera from challenged Arkansas Progressor chickens contains VNF-like activity comparable to challenged Arkansas Regressor chickens.

TABLE 8

Virus Neutralization Activity of Chicken Sera From Various Genetically Different Lines of Chickens Against Infectious Bursal Disease Virus						
Sample #	Origin	Titer ED50	Units/50 μ l	Units/ml	Protein (μ g/ml)	Specific Activity (Units/ μ g)
5079a Progressor sera #4565	Control Peak	625	25	500	650	0.8
	ARK Challenged	3,548	142	2,838		
Progressor sera #676	ARK Unchallenged	20	0.8	16		
Regressor sera #194	ARK Unchallenged	1,258	50	1,000		
Regressor sera	(Challenged-Boost)	3,162	126.4	2,528	27,430	0.1
HyLine sera	(Challenged RSV 1st)	1	0.04	0.8	24,250	

EP 0 755 684 B1

TABLE 8 (continued)

Virus Neutralization Activity of Chicken Sera From Various Genetically Different Lines of Chickens Against Infectious Bursal Disease Virus						
Sample #	Origin	Titer ED50	Units/50µl	Units/ml	Protein (µg/ml)	Specific Activity (Units/µg)
East Lansing 12733	15.C-12xC	0	0	0		
East Lansing 13133	15.Cx12	0	0	0		
East Lansing 12772	6.3x15.6	35	1.4	28		
East Lansing 12760	6.3	0	0	0		
East Lansing 12792	15.6x2	0	0	0		

EXAMPLE 10

Protection of Chicks at Hatch from Live Virus Administered In Ovo with VNF

[0063] This experiment demonstrates that VNF protects chickens at hatch from IBDV given as a vaccine in ovo at day 18 of incubation. Note that existing vaccine strains of IBDV are so infectious that they are difficult to use in ovo without severe reductions in hatchability.

[0064] The procedure described herein also provides a test for conjugates capable of serving as a vaccine.

[0065] The study consisted of 9 groups with 10-15 HYVAC embryonated eggs in each group. Standard vaccine against IBDV was provided by CEVA Laboratories, IBD-BLEN™ (1000 doses/vial). Doses of 10X, 1X, 0.1X, and 0.01X of vaccine per 50µl volume were prepared. VNF was used at 800 µg/50µl volume as a 1X dose and doses of VNF were prepared in 1X (800µg) and .1X dose (80 µg)/50µl amounts. For in ovo injection 50µl IBD-BLEN and 50µl VNF were mixed and made up to 200µl total volume using CEVA diluent. Various doses of IBD-BLEN plus VNF were administered as vaccines, and various doses of IBD-BLEN vaccine alone were used to vaccinate the 18 day old embryos. Table 9 lists the vaccine treatments that the various groups received. The birds were allowed to hatch and were grown out in separate groups to day 5 post hatch. At this time the birds were weighed and the bursas weighed and examined.

[0066] Nine groups of bursas, three per group, were submitted for histological evaluation. These tissues were graded in the following manner: 0 = normal; 1 = minimal change (which includes slight irregularity to the surface mucosa, some depletion of lymphocytes in some follicles with the normal size); 2 = mild changes -- mild invaginations, with some depletion of lymphocytes and some atrophy of the follicles (this will also include some inflammatory changes with no necrosis); 3 = moderate changes -- more extensive invagination of the mucosa with the folds being reduced in size (most follicles will be atrophic and/or depleted or lymphocytes, more extensive inflammation or necrosis); 4 = extensive changes -- folds obviously atrophied (inter- follicular epithelium will be depressed in the folds causing some vacuole-like formation. This will include no normal follicles with more extensive inflammation or necrosis); 5 = severe -- normal architecture is severely disrupted, folds markedly reduced in size. This may also include extensive inflammation or necrosis.

[0067] Tables 9 and 10 show the body weight gains, percentage of hatch, bursal weight, and bursa histology among various groups. Birds receiving the 10X dose IBD-BLEN + 1X dose VNF showed significantly greater hatchability (100%) than those receiving the 10X dose of IBD-BLEN alone (55%). The same was true at the 1X vaccine dose level. Body weight gain was decreased (5 to 9 grams) in birds receiving the 1X, 0.1X, and 0.01X IBD-BLEN vaccine dose alone (Table 11) when compared to uninoculated controls (14.8 grams). However, when VNF was added to these same doses of IBD-BLEN, the body weight gain was significantly increased (17 to 18 grams).

[0068] Essentially the same effect was seen on bursa weight as on body weight gain. The IBD-BLEN doses alone produced bursal atrophy and bursa weight loss (0.04 to 0.06 gram) by day 5 when compared to controls (0.13 gram). The addition of VNF with vaccine resulted in bursas with normal weight (0.12 to 0.15 gram) (Table 10). However, the

EP 0 755 684 B1

bursal histology showed that a ratio in the vaccine of 1X virus to 10X VNF was required to more completely protect the bursa from IBDV infection. A 1X virus to 1X VNF ratio with vaccine protected hatchability, body weight gain, and bursal weight, but did not prevent some un-neutralized virus from causing bursal lymphocyte depletion (Table 10).

5

TABLE 9

In Ovo Vaccination with IBD-BLEN™ and VNF and Effect on Hatchability and Body Weight Gain from Day 0 to Day 5				
	Mean Body Weight (g)	SEM	n	% Hatch
PERCENT HATCH AND BODY WEIGHT GAIN FROM DAY 0 TO DAY 5				
IBD-BLEN 10X ¹	.	.	1	55
IBD-BLEN 10X + VNF-1(1X) ²	11.39 ^{BC}	1.91	11	100
IBD-BLEN 1X	5.01 ^D	2.55	10	83
IBD-BLEN 1X + VNF-1(1X)	18.33 ^A	1.49	11	92
IBD-BLEN 0.1X	7.70 ^{CD}	1.53	9	91
IBD-BLEN 0.1X + VNF-2(0.1X)	16.43 ^A	1.64	10	91
IBD-BLEN 0.01X	8.99 ^{CD}	1.26	10	91
IBD-BLEN 0.01X + VNF-2(0.1X)	17.52 ^A	1.50	10	100
Positive Control (No Vaccination)	14.80 ^{AB}	1.21	11	100

Treatment was significant at the 0.05 level for groups with different superscripts.

10

15

20

25

30

¹ A 1X dose of IBD-BLEN represents an ED₅₀ titer value of 1:500.

² A 1X dose of VNF represents 800 µg/dose.

35

TABLE 10

In Ovo Vaccination with IBD-BLEN™ and VNF and Effect on Bursa Weight and Histology				
	Mean Bursal Weight (g)	SEM	n	Bursa Histology Scores
IBD-BLEN 10X	.	.	1	3,3
IBM-BLEN 10X + VNF-1(1X)	0.07 ^B	0.01	11	3,3,3
IBD-BLEN 1X	0.04 ^B	0.00	10	3,4,4
IBD-BLEN 1X + VNF-1(1X)	0.12 ^A	0.02	11	3,3,3
IBD-BLEN 0.1X	0.06 ^B	0.00	9	3,4,3
IBD-BLEN 0.1X + VNF-2(0.1X)	0.11 ^A	0.01	10	3,3,4
IBD-BLEN 0.01X	0.06 ^B	0.01	6	3,3,5
IBD-BLEN 0.01X + VNF-2(0.1X)	0.15 ^A	0.02	6	0,0,2
Positive Control	0.13 ^A	0.01	8	0,0,1

Treatment was significant at the 0.05 level for groups with different superscripts.

55

EXAMPLE 11

Immunization of Chicks by Administration of VNF and Live Virus In Ovo

5 **[0069]** This Example extends Example 10 above by demonstrating that a VNF-IBDV conjugate actually immunizes chickens against Infectious Bursal Disease Virus (IBDV). In this experiment, VNF was preincubated with CEVA IBD-BLEN™ vaccine, the vaccine provided at recommended and less than optimal concentrations, and the mixture administered in ovo to embryonated eggs prior to live challenge with USDA-IBDV at day 39 post vaccination (or day 35 post hatch).

10 **[0070]** The study consisted of ten groups. HYVAC eggs were used in Groups 1-6 and SPAFAS eggs were used in Groups 7-10. Each group was housed in a separate isolation unit and all units were located in the same room. Treatments differed by materials being administered and by methods of administration. Treatment groups, doses, and sample sizes are given in Table 11 below.

15 **[0071]** Baseline data was collected from positive control groups (Groups 1 and 7), and from negative control groups (Groups 2 and 8). Fertile, viable SPAFAS-SPF and HYVAC eggs were vaccinated by in ovo manual injection on Day 18 of incubation. Injection was through the top of the egg into the amnion. The volume of injection was 200 µl. Parameters measured were hatchability, hatch weight, IBD antibody titer, body weight, bursa weight, and bursa histology.

TABLE 11

20

Treatment Groups, Doses, and Sample Sizes					
Group No.	Treatment Description	CEVA Vaccine Dose In Ovo	USDA-IBDV Dose (PFU) Day 35 Post Hatch	VNF Dose (µg)	Est. # of Eggs
HYVAC EGGS					
1	Positive Control		47		21
2	Negative Control IBD-BLEN™ Vaccine (1X) ¹	1X	47		38
3	IBD-BLEN™ (1X) + VNF (Dose 1) ²	1X	47	800	22
4	IBD-BLEN™ (1X) + VNF (Dose 2)	1X	47	80	22
5	IBD-BLEN™ (1X) + VNF (Dose 3)	1X	47	8	38
6	VNF Alone (Dose 1)		47		21
SPAFAS EGGS					
7	Positive Control		47		25
8	Negative Control IBD-BLEN™ Vaccine (0.1X)	0.1X	47		25

25

30

35

40

45

50

55

¹A 1X dose (or standard dose) of IBD-BLEN represents an ED₅₀ titer value of 1:500.

²VNF dose 1 = 1 standard VNF dose (800 µg/dose), VNF dose 2 = 0.1X standard VNF dose, and VNF dose 3 = 0.01X standard VNF dose.

EP 0 755 684 B1

TABLE 11 (continued)

SPAFAS EGGS						
5	9	IBD-BLEN™ (0.1X) + VNF (Dose 1)	0.1X	47	800	25
10	10	IBD-BLEN™ (0.1X) + VNF (Dose 2)	0.1X	47	80	25

[0072] The results of this experiment are illustrated in Tables 12 to 15 below. HYVAC birds that received VNF mixed with IBD-BLEN demonstrated increased hatchability (82%) as compared to those that received vaccine alone (32%), and better hatchability was seen at the higher concentrations of VNF (82-47%) (Table 12). The SPAFAS hatchability cannot be compared (Table 12) due to other problems encountered during hatch. However, those remaining alive for the rest of the study represent reliable birds for examination of study parameters. Mortality to day 35 was greater in those groups receiving vaccine alone or in vaccine combination with the lower doses of VNF (Table 12). Higher doses of VNF protected against high mortality when mixed with the vaccine (data was similar to controls).

[0073] HYVAC birds that received VNF mixed with IBD-BLEN showed normal weight gain (45-59 grams) after challenge with USDA-IBDV but the nonvaccinated birds showed low weight gain (5.6 grams) (Table 13). Vaccination with VNF alone did not offer protection against the USDA challenge. Also, mortality for these groups was reduced when compared to unvaccinated controls (Table 12).

[0074] In general, a higher VNF to virus ratio offered increased protection to the bursa after USDA challenge (Table 14). Control bursas receiving no vaccine were severely hemorrhagic and edemic after challenge (Table 14). Birds receiving vaccine alone had severely atrophied bursas, and birds receiving vaccine and VNF had partially atrophied bursas after challenge.

[0075] Birds that were vaccinated with the mixture of IBD-BLEN and VNF showed significantly greater antibody titers to USDA-IBDV challenge than those receiving the IBD-BLEN alone (Table 15). This indicates that these birds would have carried a much higher protection after vaccination to any secondary infections throughout growout as compared to those receiving the virus vaccine alone. Again, one can see that antibody titer begins to fall off at the lowest dose of VNF when mixed with virus. This indicates that, if too much damage is caused to the bursa at vaccination, protection in terms of antibody titer is lost throughout the rest of the life of the bird.

TABLE 12

In Ovo Vaccination with IBD-BLEN™ and VNF and Effect on Hatchability and Mortality						
Group No.	Hatchability		Mortality by D35		Mortality Post Chal	
	n	%	n	%	n	%
1	16/21	76.2 ^A	0/16	0.0 ^A	7/16	43.8 ^B
2	12/38	31.6 ^B	4/12	33.0 ^A	0/8	0.0 ^B
3	18/22	81.8 ^A	0/18	0.0 ^A	1/18	5.6 ^B
4	16/22	72.7 ^A	1/16	6.3 ^A	0/15	0.0 ^B
5	18/38	47.4 ^{AB}	5/18	27.8 ^A	1/13	7.7 ^B
6	15/21	71.4 ^{AB}	0/15	0.0 ^A	2/15	13.3 ^B
7	13/25	52.0 ^a	7/13	53.8 ^{ab}	1/6	16.6 ^A
8	11/25	44.0 ^a	10/11	90.9 ^a	0/1	0.0 ^A
9	7/25	28.0 ^a	1/7	14.3 ^b	0/6	0.0 ^A
10	8/25	32.0 ^a	0/8	0.0 ^b	0/8	0.0 ^A

Different superscripts designate significant differences by chi square analysis.

EP 0 755 684 B1

TABLE 13

In Ovo Vaccination with IBD-BLEN™ and VNF and Effect on Body Weight Gain of SPF Chickens After USDA-IBDV Challenge on Day 35 Post Hatch			
Group No.	Mean (g)	SEM	n
WEIGHT GAIN FROM DAY 35 TO DAY 39			
1	5.61 ^B	6.99	9
2	59.29 ^A	3.63	8
3	45.64 ^A	1.81	17
4	56.26 ^A	2.94	15
5	50.28 ^A	5.98	12
6	16.33 ^B	4.80	13
7	18.20 ^c	0.62	5
8	57.90		1
9	43.35 ^b	6.26	6
10	62.60 ^a	4.64	8

Means with different superscripts differed significantly at the 0.05 level. (The SPAFAS 0.1X treatment was not included in the statistical analyses).

TABLE 14

Bursa Weight of SPF Chicken Groups After In Ovo Vaccination and Day 35 Post Hatch USDA-IBDV Challenge			
Group No.	Mean (g)	SEM	n
BURSA WEIGHT DAY 39			
1	2.03 ^A	0.29	9
2	0.55 ^B	0.20	8
3	0.73 ^B	0.07	17
4	0.62 ^B	0.12	15
5	0.47 ^B	0.09	12
6	2.05 ^A	0.11	13
7	2.28 ^a	0.23	5
8	0.29	--	1
9	0.57 ^b	0.11	6
10	0.77 ^b	0.12	8

Means with different superscripts differed significantly at the 0.05 level. (The SPAFAS 0.1X treatment was not included in the statistical analyses).

TABLE 15

In Ovo Vaccination with IBD-BLEN™ and VNF and Effect on Antibody Titer After USDA-IBDV Challenge TITERS (LOG 10)					
Group No.	Mean	SD	SEM	n	Inverse Log Mean Titer
1	0.66 ^C	0.71	0.24	9	4.57
2	2.15 ^B	0.93	0.33	8	141.25 ¹
3	3.33 ^A	0.29	0.07	17	2137.96 ²
4	3.31 ^A	0.40	0.10	15	2041.74
5	2.95 ^A	0.76	0.22	12	891.25
6	0.61 ^C	0.59	0.17	12	4.07

¹In Group 2, 13% of the birds had titers greater than 1,000 and 87% had titers less than 1,000.

²In Group 3, 82% of the birds had titers greater than 1,000 and only 18% had titers less than 1,000.

EP 0 755 684 B1

TABLE 15 (continued)

In Ovo Vaccination with IBD-BLEN™ and VNF and Effect on Antibody Titer After USDA-IBDV Challenge TITERS (LOG 10)					
Group No.	Mean	SD	SEM	n	Inverse Log Mean Titer
7	0.85 ^b	0.54	0.24	5	7.08
8	0.30	0.00	0.00	1	2.00
9	3.30 ^a	0.20	0.08	6	1995.26
10	3.25 ^a	0.62	0.22	8	1778.28

Means with different superscripts differed significantly at the 0.05 level.

EXAMPLE 12

Alternate Sources of VNF as Determined by the Chicken Fibroblast Assay

[0076] This Example demonstrates alternate sources of VNF with the chicken fibroblast assay described in Example 7 above.

[0077] Table 16 illustrates the viral neutralization titers against IBDV of serum samples from various birds as well as the corresponding Elisa titers. From this data one can see that some serum samples (HyLine chicken) have very high Elisa titers with correspondingly low viral neutralization titer. Hence, it is possible to have antibodies that bind very strongly to IBDV but do not neutralize IBDV. The HyLine chicken was challenged with RSV, regressed tumors, and produced binding antibodies against IBDV, but did not produce viral neutralizing antibodies against IBDV. The Arkansas regressor line chicken serum sample has both binding and neutralizing activity against IBDV.

[0078] An interesting observation is that unchallenged Jungle Fowl chickens from both the University of Arkansas and Mississippi State University produce serum with neutralizing antibodies against IBDV. Note also that Table 16 shows that VNF-like activity is found in the serum of a SPAFAS chicken that was inoculated with IBDV.

TABLE 16

Viral Neutralizing Activity and Elisa Titer of Various Serum Samples, VNF (5077D), and SPAFAS IBDV Antisera Against IBDV					
Sample Origin	ED ⁵⁰ Titer	Units 50 µl	Units/ ml	Units/ ml ¹	Elisa Titer
VNF Peak II - TSK (1:4 dilution) (5077 D)	2,238	89.5	1,790	7,161	102,400
SPAFAS IBDV Antisera (1:100 dilution)	251	10	200	20,000	81,800
University of Arkansas Jungle Fowl (1:10 dilution)	398	15.9	318	3,180	25,600
University of Arkansas Regressor line sera (1:10 dilution)	112	4.5	90	900	12,800
Mississippi State University Jungle Fowl sera (1:10 dilution)	316	12.6	252	2,520	12,800
HyLine SC Line sera (1:5 dilution)	3.1	0.12	2.4	12	819,200
Unchallenged University of Arkansas (1:5 dilution) Progressor line sera	3.9	0.15	3	15	12,800
Challenged University of Arkansas (1:5 dilution) Progressor line sera	501	20	400	2,000	12,800

¹Units corrected for dilution of original sample.

EXAMPLE 13

In Situ Vaccination Potential of VNF with Infectious Bursal Disease Virus

5 [0079] The object of this experiment was to test the efficacy of the VNF-IBD-BLEN™ mixture when administered by IM injection to chickens on 1-2 day post hatch to stimulate immunity to a secondary challenge of USDA-IBDV challenge virus.

[0080] Approximately 160 healthy 1 or 2 day old Hy-Vac chickens that are very susceptible to IBD-BLEN™ strain and are typically used in regulatory studies for licensing vaccines were used. Challenge of vaccinated birds was carried
10 out with USDA Challenge Strain of Infectious Bursal Disease Virus (USDA-IBDV-CV) Lot #83-1, $10^{3.8}$ EID₅₀/ml. Standard vaccine against IBDV was obtained from SANOFI (IBD-BLEN™) at 1000 doses/vial, $10^{2.7}$ EID₅₀/dose. VNF from Arkansas regressor line birds as prepared as described above, 16,000µg/ml in 1.5X Phosphate Buffered Saline, (PBS) pH 7.4. Its activity is determined by its viral neutralizing activity against Lukert's Strain of IBDV using Hy-Vac chicken fibroblasts in microneutralization assays. Purity was checked by HPLC.

15 [0081] Each chicken receiving the IBD-BLEN™ 1X or .1X dose vaccine received 100µl of the IBD-BLEN™ preparation by IM injection into the thigh of the left leg. The 100µl total volume will be composed of 50µl IBD-BLEN™ (1X or 0.1X) + 50µl CEVA diluent. (Group 2 - 1X dose, Group 5 - 0.1X dose).

[0082] Each chicken receiving the IBD-BLEN™ 1X + VNF (Dose 1 or Dose 2) or 0.1X + VNF (Dose 1), received 100µl of the vaccine mixture by IM injection. The 100µl total volume was composed of 50µl IBD-BLEN™ (1X or 0.1X)
20 + 50µl VNF (Dose 1 or Dose 2). (Group 3 - IBD-BLEN™ (1X) + VNF - Dose 1, Group 4 - IBD-BLEN™ (1X) + VNF - Dose 2, Group 6 - IBD-BLEN™ (0.1X) + VNF - Dose 1).

[0083] Each chicken receiving the VNF alone received 100µl of the VNF preparation by IM injection. The 100µl total volume will be composed of 50µl VNF - Dose 1 + 50µl CEVA diluent. (Group 7).

25 [0084] Each chicken receiving the USDA-IBDV challenge virus on Day 21 post vaccination will receive 30µl of the preparation by eye drop in each eye. The 60µl total volume required for both eyes is composed from a preparation of 1:8 dilution of stock USDA-IBDV virus which is 6309 EID₅₀/ml. (1.4ml USDA-IBDV + 9.8ml CEVA diluent - 23.5 EID₅₀/30µl)

30 [0085] Data from this experiment are given in Table 17 below. Note that the birds in group 6 showed protection by day 10 from the vaccine virus in the virus-VNF conjugate. Hence, data from this study shows that it is possible to neutralize or inhibit a 0.1X dose of IBD-BLEN™ with 136 units of VNF so as to protect the bursa from the virus in the virus-VNF conjugate until day 10. Furthermore, when these birds are challenged on day 29 with USDA challenge strain, they show protection (no body weight loss, no mortality) from the challenge.

35

40

45

50

55

TABLE 17
Summary of Body Weight Gain, Bursa Parameters,
and IBD Antibody Titers for Example 13

Treatment Group	VNF Units/ 50µl	Number Birds/ Group	Body Weight Gain Day Day 0-35 35-40	Average Bursal Weight (gr)		Percent Lymphocytes Remaining in Bursa		IBDV Antibody Titer (%HI)			Percent Mortality Day 35-40
				Day 10	Day 40	Day 10	Day 40	Day 10	Day 35	Day 40	
SPF											
1 Control		7	^A 401 ^D 9	^{AB} 0.45	^A 2.1	100	0	^B 5	^B 41	^C 419	50
2 VACC 1X		22	^C 337 ^C 44	^C 0.12	^B 0.8	20	60	^A 347	^A 1664(40)	^B 1763(50)	0
3 VACC 1X VNF-1 (800µg)	136	13	^{AB} 381 ^{BC} 49	^{AB} 0.50	^B 0.7	35	38	^B 2	^A 3105(90)	^A 3778(92)	0
4 VACC 1X VNF-2 (80µg)	14	16	^{ABC} 365 ^{AB} 59	^C 0.15	^B 0.6	0	40	^A 158	^A 2172(60)	^{AB} 3163(68)	0
5 VACC 0.1X	23		^{AB} 372 ^{BC} 55	^C 0.13	^B 1.0	5	78	^A 467	^A 1805(75)	^{AB} 2705(77)	0
6 VACC 0.1X VNF-1 (800µg)	136	13	^A 379 ^A 69	^A 0.58	^B 0.5	90	15	^B 2	^A 2885(60)	^A 4255(81)	0
7 VNF-1 (800µg)	136	15	^{BC} 343 ^D 6	^B 0.39	^A 1.6	100	0	^B 3	^B 41	^D 78	10

(%) = % of birds with ≥ 1000 IBDV antibody titer
^{ABCD} Means with different superscripts differed significantly at the 0.05 level.

EXAMPLE 14

In situ Vaccination Potential of HyLINE Sera with SANOFI IBD-BLEN™ Vaccine When Administered Subcutaneously to HyVAC SPF Chickens

5

[0086] The object of this experiment was to evaluate immunological and pathological changes in terms of antibody titers and bursa parameters at 21 days of age in chickens receiving inoculations of SANOFI IBD-BLEN™ that has been incubated with SC HyLINE sera and administered as a complete vaccine conjugate subcutaneously into the bird's neck.

10

[0087] Healthy one (1) day old HyVAC SPF chickens (about 90 total.) that are susceptible to IBD-BLEN™ vaccination and USDA-IBDV challenge were used in these studies.

[0088] SC-Sera ($\approx 35,000\mu\text{g/ml}$, #SC-2-22-90, ED_{50}/ml of 1:3,000,000) is whole sera which contains VNF and is produced by boosting SC HyLINE chickens with SANOFI IBD-BLEN™ in accordance with known procedures. VNF activity in this sera is determined by viral neutralization assays as described above.

15

[0089] IBD-BLEN™, and SC HyLINE sera were stored at 4°C until ready for use. Once prepared, the IBD-BLEN™ vaccine and Sera-IBD- BLEN™ mixtures were held at room temperature for one (1) hour before inoculation.

[0090] Data for the various experimental and control groups in this study are given in Table 18. These data demonstrate that, at concentrations of VNF equal to or greater than 316 Units, the bursa can be protected by weight at day 22 from the vaccine virus in the vaccine serum conjugate given at day 1.

20

25

30

35

40

45

50

55

TABLE 18

Day 1 Posthatch Dose Titration Vaccination in SPF Chickens
Using SANOFI IBD-BLEN™ Plus Viral Neutralization Factor (VNF) and
Evaluation of Bursal Parameters at Day 21 Posthatch (Example 14)

Group Number	IBDV-BLEN™ Dose ¹	VNF Units ²	Body Weight	Bursa Weight	Relative Bursa Weight (g/kg)	Bursal Index	Titer Log-10	Titer INV Log
15	Negative Control		A 178.8	A 1.07	A 5.94	A 100.00	C 0.52	3
16	0.01X	0	A 168.67	B .27	B 1.57	B 26.44	A 3.10	1259
17	0.01X	3159	A 177.4	A 1.06	A 5.73	A 96.48	B 1.0	11
18	0.01X	316	A 178.8	A 1.01	A 5.61	A 94.48	C 0.30	2
19	0.01X	32	A 157.0	B 0.25	B 1.63	B 27.53	A 2.63	427
20	0.01X	3.2	A 173.1	B 0.25	B 1.44	B 24.29	A 2.67	468

A, B, C = Means in a column processing different superscripts differed significantly at the 0.05 level

¹ A 0.01X dose of SANOFI IBD-BLEN™ is 2.24 EID50/dose (Lot #29967).

² Viral neutralization activity expressed as units/50µl dose.

EXAMPLE 15

Minimum Protective Dose of SC HyLINE Serum with Infectious Bursal Disease Virus Vaccine Administered Subcutaneously to HyVAC SPF Chickens

5

[0091] SANOFI IBD-BLEN™ is a virulent live virus vaccine capable of causing acute and chronic bursal lesions 3-9 days post vaccination in SPF chickens. Previous experiments utilizing this vaccine in 1 to 2 day old HyVAC SPF chickens have demonstrated bursal atrophy by day 10 to day 14 from intramuscular and subcutaneous inoculations of 1X through 0.0001X doses of IBD-BLEN™.

10

[0092] In this study, certain groups of one (1) day old HyVAC SPF chickens were vaccinated subcutaneously with various doses of SANOFI IBD-BLEN™ alone and in combination with various doses of SC HyLINE serum containing VNF. Vaccinated and control chickens were examined for bursal morphology as well as gross lesions at 15 or 22 days of age and challenged at 29 days of age with USDA-IBDV challenge strain to confirm immunogenicity (14, 21, and 28 days post vaccination). The object of this experiment is to evaluate immunological and pathological changes in terms of antibody titers and bursa parameters at 15 and 22 days of age in chickens receiving inoculations, at one (1) day of age (14, 21, and 28 days post vaccination), of various doses of SANOFI IBD-BLEN™ alone and incubated with various doses of SC HyLINE serum and administered as a complete vaccine. USDA-IBDV challenge occurred at 29 days of age.

15

[0093] Healthy one (1) day old HyVAC SPF chickens (630) that are susceptible to IBD-BLEN™ vaccination and USDA-IBDV challenge were used in this study. SC-Serum (40,000µg/ml, #5-18-90, ED₅₀/ml of ≈1:511,000) is whole serum which contains VNF and is produced by boosting SC HyLINE chickens with SANOFI IBD-BLEN™. VNF activity in this serum is determined by viral neutralization assays as described above. Commercial vaccine against IBDV, IBD-BLEN™, was provided by SANOFI Laboratories at 1000 doses/vial, 10^{2.3} EID₅₀ titer. USDA-Challenge Strain of Infectious Bursal Disease Virus, Lot #83-3, 10^{3.8} EID₅₀/ml, was used as a challenge. Vaccination was by subcutaneous injection and USDA-IBDV challenge was by eye drop at day 29 posthatch.

20

25

[0094] Data from this experiment are given in part in table 19. Our results show that, at a dose of 338 units of VNF and at a vaccine dose of 0.01x (2.24 EID₅₀/dose), bursas were protected from the vaccine virus at days 15 and 22, and were solidly immune to USDA challenge strain at day 29. After USDA challenge on day 29 there was normal body weight gain and no mortality in this group.

30

35

40

45

50

55

TABLE 19
Day 1 Posthatch Dose Titration Vaccination in SPF Chickens Using SANOFI IBD-BLEN™ Plus Viral Neutralization Factor (VNF) and Evaluation of Bursal Parameters and IBDV Antibody Titers at Day 15, Day 22, and 4 Days post USDA-IBDV Challenge¹ Given on Day 29² (Example 15)

Group Number	Isolator Number	IBDV-BLEN Dose ³	VNF Units ⁴	Bursa Weight (gm)						Relative Bursa Weight (g/kg)						IBDV Antibody Titer (ELISA)					
				Day 15		Day 22		Day 33		Day 15		Day 22		Day 33		Day 15		Day 22		Day 33	
				Day 15	Day 22	Day 15	Day 22	Day 15	Day 22	Day 15	Day 22	Day 15	Day 22	Day 15	Day 22	Day 15	Day 22	Day 15	Day 22	Day 15	Day 22
1	6	Negative Control		0.203*	0.317*	0.763*	1.54	1.54	2.04	366	917	2711									
1	17	Positive Control		0.622	1.229	2.145	4.72	5.86	5.95	10	55	4									
2	20	Control		0.600	1.151	1.064	4.57	5.83	4.02	9	104	52									
2	16	0.01x		0.710	1.222	1.576	5.18	5.91	5.55	57	67	46									
3	9	0.01x		0.222	0.362	0.890	1.67	1.80	2.27	722	824	1720									
3	2	0.01x	338	0.189	0.401	0.863	1.38	1.86	2.40	1055	1794	2480									
4	1	0.01x		0.632	0.397*	0.482*	4.76	2.12	1.30	50	696	1645									
4	3	0.01x	34	0.637	1.233	0.559	4.78	6.03	1.60	16	39	1677									
5	15	0.01x		0.641	1.166	1.866	4.74	5.78	5.71	27	11	38									
5	19	0.01x		0.552	1.081	1.436	4.27	5.66	5.06	120	3	63									
6	8	0.001x		0.194	0.423	1.177	1.48	2.03	3.04	1201	1072	2037									
6	12	0.001x		0.181	0.376	0.708	1.42	1.83	2.07	499	1182	1539									
7	13	0.001x	338	0.661	1.340	1.824	4.74	6.54	5.45	40	34	74									
7	18	0.001x		0.706	1.120	1.626	5.46	5.37	5.4	76	71	34									
8	5	0.001x	34	0.707	1.122	1.492	5.06	5.74	4.48	17	168	26									
8	11	VNF alone		0.638	1.480	1.630	4.57	6.41	4.89	114	41	37									
9	10	1:3	338	0.604	1.222	1.752	4.60	6.38	4.96	50	130	72									
9	14	VNF alone		0.624	0.983*	0.440*	4.39	5.30	1.31	58	39	1163									
10	7	1:30	34	0.190*	0.225*	0.449*	1.61	1.32	1.26	573	750	2636									
10	4	0.0001x		0.748	1.252	2.080	5.16	5.95	6.18	60	3	163									
11	12	0.0001x	3.4	0.682	1.094	1.507	5.11	5.54	5.18	86	6	28									

¹ USDA-IBDV Challenge strain administered by eye-drop at Day 29 posthatch at 47 EID₅₀/bird to every group except negative control.

² Statistical analysis not shown.

³ A 0.01x dose of SANOFI IBD-BLEN™ contained 2.24 EID₅₀/dose (Lot #29967).

⁴ Viral neutralizing activity is expressed as units/50µl dose, whole serum containing VNF from SC flyline chickens.

* Groups that were contaminated with IBDV.

Claims

1. The use of a vaccine conjugate for the manufacture of a medicament for producing active immunity against a viral disease in a mammalian animal subject, the vaccine conjugate comprising:

5 a vaccine virus consisting of a live mammalian virus capable of causing said disease in said animal and capable of producing an active immune response thereto in said animal, and
 bound to said vaccine virus a neutralizing factor in the form of an antibody or antibody fragment capable of neutralising said virus, said vaccine conjugate initially protecting said animal from infection by said vaccine virus,
 10 the vaccine conjugate subsequently allowing said vaccine virus to stimulate active immunity against further challenge with said virus.

2. The use of a vaccine conjugate according to claim 1, wherein the neutralizing factor is an IgG immunoglobulin or an IgG immunoglobulin fragment.

3. The use of a vaccine conjugate according to claim 1 or claim 2, wherein the neutralizing factor is of polyclonal origin.

4. The use of a vaccine conjugate according to claim 1 or 2, wherein the neutralizing factor is of monoclonal origin.

5. The use of a vaccine conjugate according to any preceding claim, wherein the medicament is prepared in a form for subcutaneous administration.

6. The use of a vaccine conjugate according to any one of claims 1 to 4, wherein the medicament is prepared in a form for intraperitoneal administration.

7. The use of a vaccine conjugate according to any preceding claim, wherein the medicament is in the form of a lyophilized formulation.

8. The use of a vaccine conjugate according to any preceding claim, wherein the medicament includes a pharmaceutically acceptable carrier.

9. The use of a vaccine conjugate according to claim 8, wherein said pharmaceutically acceptable carrier is a liquid carrier.

10. The use of a vaccine conjugate according to claim 9, wherein said pharmaceutically acceptable carrier is an aqueous carrier.

11. The use of a vaccine conjugate according to any preceding claim, wherein the medicament further comprises an adjuvant.

12. The use of a vaccine conjugate according to any preceding claim, wherein the medicament further comprises a stabilizer.

13. A vaccine preparation useful for producing active immunity against a viral disease in a mammalian animal subject, said vaccine preparation comprising:

a pharmaceutically acceptable formulation comprising a vaccine conjugate of live infectious disease virus and a neutralizing factor bound to said live virus;
 50 said live virus being a pathogenic virus capable of causing disease in said subject;
 said neutralizing factor selected from antibodies and antibody fragments which neutralize the live virus;
 said vaccine conjugate included in an amount effective to produce an immune response to said live virus in said subject, after initially protecting the subject from infection by the vaccine virus.

14. A vaccine preparation according to claim 13 wherein said neutralizing factor is an IgG immunoglobulin or an IgG immunoglobulin fragment.

15. A vaccine preparation according to claim 13 or claim 14, wherein said vaccine conjugate is produced by the process

of combining blood serum containing said neutralizing factor with said live virus.

5 16. A vaccine preparation according to any one of claims 13 to 15, wherein said pharmaceutically acceptable formulation is lyophilized.

17. A vaccine preparation according to any one of claims 13 to 16, wherein said pharmaceutically acceptable formulation comprises a pharmaceutically acceptable carrier.

10 18. A vaccine preparation according to claim 17, wherein said pharmaceutically acceptable carrier is a liquid carrier.

19. A vaccine preparation according to claim 18, wherein said pharmaceutically acceptable carrier is an aqueous carrier.

15 20. A vaccine preparation according to any one of claims 13 to 19, wherein said pharmaceutically acceptable formulation further comprises an adjuvant.

21. A vaccine preparation according to any one of claims 13 to 20, wherein said pharmaceutically acceptable formulation further comprises a stabilizer.

20 22. A vaccine preparation according to any one of claims 13 to 21, wherein said neutralizing factor is of polyclonal origin.

23. A vaccine preparation according to any of claims 13 to 22, wherein said neutralizing factor is of monoclonal origin.

25 24. An article of manufacture comprising a closed, pathogen-impermeable container and a sterile vaccine preparation enclosed within said container, said vaccine preparation useful for producing active immunity against a viral disease in a mammalian animal subject, said vaccine preparation comprising:

a pharmaceutically acceptable formulation comprising a vaccine conjugate of live infectious disease virus and a neutralizing factor bound to said live virus;

30 said live virus being a pathogenic virus capable of causing disease in said subject;

said neutralizing factor selected from antibodies and antibody fragments which neutralize the live virus;

said vaccine conjugate included in an amount effective to produce an immune response to said live virus in said subject, after initially protecting the subject from infection by the vaccine virus.

35 25. An article of manufacture according to claim 24 wherein said pharmaceutically acceptable formulation is lyophilized.

40 26. An article of manufacture according to claim 24 or 25 wherein said pharmaceutically acceptable formulation comprises a pharmaceutically acceptable carrier.

27. An article of manufacture according to claim 26 wherein said pharmaceutically acceptable carrier is a liquid carrier.

45 28. An article of manufacture according to Claim 27, wherein said pharmaceutically acceptable carrier is an aqueous carrier.

29. An article of manufacture according to any one of claims 24 to 28, wherein said pharmaceutically acceptable formulation further comprises an adjuvant.

50 30. An article of manufacture according to any one of claims 24 to 29, wherein said pharmaceutically acceptable formulation further comprises a stabilizer.

31. An article of manufacture according to any one of claims 24 to 30, wherein said neutralizing factor is an IgG immunoglobulin or an IgG immunoglobulin fragment.

55 32. An article of manufacture according to any one of claims 24 to 30, wherein said neutralizing factor is of polyclonal origin.

33. An article of manufacture according to any one of claims 24 to 30, wherein said neutralizing factor is of monoclonal

origin.

Patentansprüche

5

- 1. Verwendung eines Impfstoffkonjugats zur Herstellung eines Arzneimittels für das Erzeugen aktiver Immunität gegen eine Viruserkrankung in einem Säugetier, wobei das Impfstoffkonjugat umfaßt:

10

ein Vaccinia-Virus, das aus einem lebenden Säugetiervirus besteht, das diese Erkrankung in dem Säugetier verursachen und eine aktive Immunantwort darauf in dem Säugetier erzeugen kann, und gebunden an dieses Vaccinia-Virus einen Neutralisationsfaktor in der Form eines Antikörpers oder Antikörperfragments, der bzw. das das Virus neutralisieren kann, wobei das Impfstoffkonjugat anfänglich das Säugetier gegen eine Infektion durch das Vaccinia-Virus schützt, und wobei das Impfstoffkonjugat anschließend dem Vaccinia-Virus ermöglicht, die aktive Immunität gegen weitere Angriffe mit dem Virus zu stimulieren.

15

- 2. Verwendung eines Impfstoffkonjugats nach Anspruch 1, wobei der Neutralisierungsfaktor ein IgG-Immunglobulin oder ein IgG-Immunglobulin-Fragment ist.

20

- 3. Verwendung eines Impfstoffkonjugats nach Anspruch 1 oder 2, wobei der Neutralisierungsfaktor polyklonalen Ursprungs ist.

- 4. Verwendung eines Impfstoffkonjugats nach Anspruch 1 oder 2, wobei der Neutralisierungsfaktor monoklonalen Ursprungs ist.

25

- 5. Verwendung eines Impfstoffkonjugats nach einem der vorhergehenden Ansprüche, wobei das Arzneimittel in einer Form zur subkutanen Zuführung zubereitet ist.

30

- 6. Verwendung eines Impfstoffkonjugats nach einem der Ansprüche 1 bis 4, wobei das Arzneimittel in einer Form zur intraperitonealen Zuführung zubereitet ist.

- 7. Verwendung eines Impfstoffkonjugats nach einem der vorhergehenden Ansprüche, wobei das Arzneimittel die Form einer lyophilisierten Formulierung aufweist.

35

- 8. Verwendung eines Impfstoffkonjugats nach einem der vorhergehenden Ansprüche, wobei das Arzneimittel einen pharmazeutisch akzeptablen Träger aufweist.

- 9. Verwendung eines Impfstoffkonjugats nach Anspruch 8, wobei der pharmazeutisch akzeptable Träger ein flüssiger Träger ist.

40

- 10. Verwendung eines Impfstoffkonjugats nach Anspruch 9, wobei der pharmazeutisch akzeptable Träger ein wässriger Träger ist.

- 11. Verwendung eines Impfstoffkonjugats nach einem der vorhergehenden Ansprüche, wobei das Arzneimittel ferner ein Adjuvans aufweist.

45

- 12. Verwendung eines Impfstoffkonjugats nach einem der vorhergehenden Ansprüche, wobei das Arzneimittel ferner einen Stabilisator aufweist.

50

- 13. Impfstoff-Präparat zur Verwendung für das Erzeugen aktiver Immunität gegen eine Viruserkrankung in einem Säugetier, mit:

55

einer pharmazeutisch akzeptablen Formulierung, die ein Impfstoffkonjugat eines lebenden infektiösen Krankheitsvirus und eines an das lebende Virus gebundenen Neutralisierungsfaktors aufweist; wobei das lebende Virus ein pathogenes Virus ist, das eine Erkrankung in dem Säugetier verursachen kann; und wobei der Neutralisierungsfaktor aus Antikörpern und Antikörperfragmenten ausgewählt ist, die das lebende Virus neutralisieren; und wobei das Impfstoffkonjugat in einer Menge enthalten ist, die zum Erzeugen einer Immunantwort auf das

EP 0 755 684 B1

lebende Virus in dem Säugetier wirksam ist, nachdem es das Säugetier anfänglich gegen eine Infektion durch das Vaccinia-Virus schützt.

- 5 **14.** Impfstoff-Präparat nach Anspruch 13,
wobei der Neutralisierungsfaktor ein IgG-Immunglobulin oder ein IgG-Immunglobulin-Fragment ist.
- 10 **15.** Impfstoff-Präparat nach Anspruch 13 oder 14,
wobei das Impfstoffkonjugat durch das Verfahren hergestellt wird, bei dem den Neutralisierungsfaktor enthaltendes
Blutserum mit dem lebenden Virus kombiniert wird.
- 15 **16.** Impfstoff-Präparat nach einem der Ansprüche 13 bis 15,
wobei die pharmazeutisch akzeptable Formulierung lyophilisiert ist.
- 15 **17.** Impfstoff-Präparat nach einem der Ansprüche 13 bis 16,
wobei die pharmazeutisch akzeptable Formulierung einen pharmazeutisch akzeptablen Träger aufweist.
- 20 **18.** Impfstoff-Präparat nach Anspruch 17,
wobei der pharmazeutisch akzeptable Träger ein flüssiger Träger ist.
- 20 **19.** Impfstoff-Präparat nach Anspruch 18,
wobei der pharmazeutisch akzeptable Träger ein wässriger Träger ist.
- 25 **20.** Impfstoff-Präparat nach einem der Ansprüche 13 bis 19,
wobei die pharmazeutisch akzeptable Formulierung ferner ein Adjuvans aufweist.
- 25 **21.** Impfstoff-Präparat nach einem der Ansprüche 13 bis 20,
wobei die pharmazeutisch akzeptable Formulierung ferner einen Stabilisator aufweist.
- 30 **22.** Impfstoff-Präparat nach einem der Ansprüche 13 bis 21,
wobei der Neutralisierungsfaktor polyklonalen Ursprungs ist.
- 30 **23.** Impfstoff-Präparat nach einem der Ansprüche 13 bis 22,
wobei der Neutralisierungsfaktor monoklonalen Ursprungs ist.
- 35 **24.** Erzeugnis mit einem geschlossenen, für Krankheitserreger undurchlässigen Behälter und einem in dem Behälter
eingeschlossenen, sterilen Impfstoff-Präparat, wobei das Impfstoff-Präparat für das Erzeugen aktiver Immunität
gegen eine Viruserkrankung in einem Säugetier verwendbar ist und umfaßt:
- 40 eine pharmazeutisch akzeptable Formulierung mit einem Impfstoff-konjugat aus einem lebenden infektiösen
Krankheitsvirus und einem Neutralisierungsfaktor, der an das lebende Virus gebunden ist;
wobei das lebende Virus ein pathogenes Virus ist, das eine Krankheit in dem Säugetier verursachen kann; und
wobei der Neutralisierungsfaktor aus Antikörpern und Antikörperfragmenten ausgewählt ist, die das lebende
Virus neutralisieren; und
wobei das Impfstoffkonjugat in einer Menge vorhanden ist, die zum Erzeugen einer Immunantwort auf das
45 lebende Virus in dem Säugetier wirksam ist, nachdem es das Säugetier anfänglich gegen eine Infektion durch
das Vaccinia-Virus schützt.
- 50 **25.** Erzeugnis nach Anspruch 24,
wobei die pharmazeutisch akzeptable Formulierung lyophilisiert ist.
- 50 **26.** Erzeugnis nach Anspruch 24 oder 25,
wobei die pharmazeutisch akzeptable Formulierung einen pharmazeutisch akzeptablen Träger aufweist.
- 55 **27.** Erzeugnis nach Anspruch 26,
wobei der pharmazeutisch akzeptable Träger ein flüssiger Träger ist.
- 55 **28.** Erzeugnis nach Anspruch 27,
wobei der pharmazeutisch akzeptable Träger ein wässriger Träger ist.

EP 0 755 684 B1

29. Erzeugnis nach einem der Ansprüche 24 bis 28,
wobei die pharmazeutisch akzeptable Formulierung ferner ein Adjuvans aufweist.

5 30. Erzeugnis nach einem der Ansprüche 24 bis 29,
wobei die pharmazeutisch akzeptable Formulierung ferner einen Stabilisator aufweist.

31. Erzeugnis nach einem der Ansprüche 24 bis 30,
wobei der Neutralisierungsfaktor ein IgG-Immunglobulin oder ein IgG-Immunglobulin-Fragment ist.

10 32. Erzeugnis nach einem der Ansprüche 24 bis 30,
wobei der Neutralisierungsfaktor polyklonalen Ursprungs ist.

33. Erzeugnis nach einem der Ansprüche 24 bis 30,
wobei der Neutralisierungsfaktor monoklonalen Ursprungs ist.

15

Revendications

20 1. Utilisation d'un conjugué vaccinal pour la fabrication d'un médicament pour produire une immunité active contre
une maladie virale chez un sujet animal mammifère, le conjugué vaccinal comprenant :

25 un virus vaccinal comprenant un virus mammifère vivant capable de provoquer ladite maladie chez ledit animal
et capable de produire une réponse immunitaire active contre celui-ci chez ledit animal, et
lié audit virus vaccinal, un facteur neutralisant sous la forme d'un anticorps ou d'un fragment d'anticorps ca-
pable de neutraliser ledit virus, ledit conjugué vaccinal protégeant initialement ledit animal d'une infection par
ledit virus vaccinal,
le conjugué vaccinal permettant ultérieurement audit virus vaccinal de stimuler une immunité active contre
une exposition ultérieure audit virus.

30 2. Utilisation d'un conjugué vaccinal suivant la revendication 1, dans lequel le facteur neutralisant est une immuno-
globuline IgG ou un fragment d'immunoglobuline IgG.

35 3. Utilisation d'un conjugué vaccinal suivant la revendication 1 ou la revendication 2, dans lequel le facteur neutralisant
est d'origine polyclonale.

40 4. Utilisation d'un conjugué vaccinal suivant la revendication 1 ou 2, dans lequel le facteur neutralisant est d'origine
monoclonale.

45 5. Utilisation d'un conjugué vaccinal suivant l'une quelconque des revendications précédentes, dans lequel le médi-
cament est préparé sous une forme destinée à une administration sous-cutanée.

50 6. Utilisation d'un conjugué vaccinal suivant l'une quelconque des revendications 1 à 4, dans lequel le médicament
est préparé sous une forme destinée à une administration intrapéritonéale.

55 7. Utilisation d'un conjugué vaccinal suivant l'une quelconque des revendications précédentes, dans lequel le médi-
cament est sous la forme d'une formulation lyophilisée.

8. Utilisation d'un conjugué vaccinal suivant l'une quelconque des revendications précédentes, dans lequel le médi-
cament comprend un vecteur acceptable sur le plan pharmaceutique.

9. Utilisation d'un conjugué vaccinal suivant la revendication 8, dans lequel ledit vecteur acceptable sur le plan phar-
maceutique est un vecteur liquide.

10. Utilisation d'un conjugué vaccinal suivant la revendication 9, dans lequel ledit vecteur acceptable sur le plan phar-
maceutique est un vecteur aqueux.

11. Utilisation d'un conjugué vaccinal suivant l'une quelconque des revendications précédentes, dans lequel le médi-
cament comprend en outre un adjuvant.

EP 0 755 684 B1

12. Utilisation d'un conjugué vaccinal suivant l'une quelconque des revendications précédentes, dans lequel le médicament comprend en outre un stabilisant.

5 13. Préparation vaccinale utile pour produire une immunité active contre une maladie virale chez un sujet animal mammifère, ladite préparation vaccinale comprenant :

une formulation acceptable sur le plan pharmaceutique comprenant un conjugué vaccinal d'un virus vivant de maladie infectieuse et un facteur neutralisant lié audit virus vivant;

10 ledit virus vivant étant un virus pathogène capable de provoquer une maladie chez ledit sujet;

ledit facteur neutralisant étant sélectionné parmi des anticorps et des fragments d'anticorps qui neutralisent le virus vivant;

ledit conjugué vaccinal étant inclus en une quantité efficace pour produire une réponse immunitaire contre ledit virus vivant chez ledit sujet, après protection initiale du sujet d'une infection par le virus vaccinal.

15 14. Préparation vaccinale suivant la revendication 13, dans laquelle ledit facteur neutralisant est une immunoglobuline IgG ou un fragment d'immunoglobuline IgG.

15 15. Préparation vaccinale suivant la revendication 13 ou la revendication 14, dans laquelle ledit conjugué vaccinal est produit par le procédé de combiner du sérum sanguin contenant ledit facteur neutralisant avec ledit virus vivant.

20 16. Préparation vaccinale suivant l'une quelconque des revendications 13 à 15, dans laquelle ladite formulation acceptable sur le plan pharmaceutique est lyophilisée.

25 17. Préparation vaccinale suivant l'une quelconque des revendications 13 à 16, dans laquelle ladite formulation acceptable sur le plan pharmaceutique comprend un vecteur acceptable sur le plan pharmaceutique.

18. Préparation vaccinale suivant la revendication 17, dans laquelle ledit vecteur acceptable sur le plan pharmaceutique est un vecteur liquide.

30 19. Préparation vaccinale suivant la revendication 18, dans laquelle le vecteur acceptable sur le plan pharmaceutique est un vecteur aqueux.

35 20. Préparation vaccinale suivant l'une quelconque des revendications 13 à 19, dans laquelle ladite formulation acceptable sur le plan pharmaceutique comprend en outre un adjuvant.

21. Préparation vaccinale suivant l'une quelconque des revendications 13 à 20, dans laquelle ladite formulation acceptable sur le plan pharmaceutique comprend en outre un stabilisant.

40 22. Préparation vaccinale suivant l'une quelconque des revendications 13 à 21, dans laquelle ledit facteur neutralisant est d'origine polyclonale.

23. Préparation vaccinale suivant l'une quelconque des revendications 13 à 22, dans laquelle ledit facteur neutralisant est d'origine monoclonale.

45 24. Article de fabrication comprenant un conteneur fermé, étanche aux pathogènes et une préparation vaccinale stérile enfermée à l'intérieur dudit conteneur, ladite préparation vaccinale étant utile pour produire une immunité active contre une maladie virale chez un sujet animal mammifère, ladite préparation vaccinale comprenant :

50 une formulation acceptable sur le plan pharmaceutique comprenant un conjugué vaccinal d'un virus vivant de maladie infectieuse et un facteur neutralisant lié audit virus vivant;

ledit virus vivant étant un virus pathogène capable de provoquer une maladie chez ledit sujet;

ledit facteur neutralisant étant sélectionné parmi des anticorps et des fragments d'anticorps qui neutralisent le virus vivant;

55 ledit conjugué vaccinal étant inclus en une quantité efficace pour produire une réponse immunitaire contre ledit virus vivant chez ledit sujet, après protection initiale du sujet d'une infection par le virus vaccinal.

25. Article de fabrication suivant la revendication 24, dans lequel ladite formulation acceptable sur le plan pharmaceutique est lyophilisée.

EP 0 755 684 B1

26. Article de fabrication suivant la revendication 24 ou 25, dans lequel ladite formulation acceptable sur le plan pharmaceutique comprend un vecteur acceptable sur le plan pharmaceutique.

5 27. Article de fabrication suivant la revendication 26, dans lequel ledit vecteur acceptable sur le plan pharmaceutique est un vecteur liquide.

28. Article de fabrication suivant la revendication 27, dans lequel le vecteur acceptable sur le plan pharmaceutique est un vecteur aqueux.

10 29. Article de fabrication suivant l'une quelconque des revendications 24 à 28, dans lequel ladite formulation acceptable sur le plan pharmaceutique comprend en outre un adjuvant.

30. Article de fabrication suivant l'une quelconque des revendications 24 à 29, dans lequel ladite formulation acceptable sur le plan pharmaceutique comprend en outre un stabilisant.

15 31. Article de fabrication suivant l'une quelconque des revendications 24 à 30, dans lequel ledit facteur neutralisant est une immunoglobuline IgG ou un fragment d'immunoglobuline IgG.

20 32. Article de fabrication suivant l'une quelconque des revendications 24 à 30, dans lequel ledit facteur neutralisant est d'origine polyclonale.

33. Article de fabrication suivant l'une quelconque des revendications 24 à 30, dans lequel ledit facteur neutralisant est d'origine monoclonale.

25

30

35

40

45

50

55

OVERVIEW OF PRIOR AND NEW VIRAL NEUTRALIZATION
FACTOR PURIFICATION PROCEDURES




FIG. 1.

FLOW CHART OF VIRAL NEUTRALIZING FACTOR PURIFICATION




FIG. 2.

FLOW CHART OF VIRAL NEUTRALIZING FACTOR
PURIFICATION IN RELATION TO ELUTION PROFILES




FIG. 3.

